Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

New Study Shows 1.2 Million People in the United States Estimated to be Living with Parkinson’s Disease by 2030

Parkinson’s Foundation Reveals Most Comprehensive Estimate of
Parkinson’s Prevalence in North America since the 1970’s

NEW YORK & MIAMI, July 10, 2018 — A Parkinson’s Foundation study recently published in the scientific journal, npj Parkinson’s Disease, reveals findings from the most comprehensive estimate of Parkinson’s disease in the United States and Canada to date. The Foundation’s “Parkinson’s Prevalence Project” estimates that 930,000 people in the United States will be living with the disease by 2020, further increasing to 1.2 million people by 2030.

"Our knowledge of Parkinson’s has evolved significantly and so should our understanding of the population that has this disease,” said James Beck, PhD, Parkinson’s Foundation Chief Scientific Officer and contributing author on the study. “These findings will help attract the attention of federal and state government as well as the pharmaceutical industry to the growing need and urgency in addressing Parkinson’s disease.”

The Parkinson’s Foundation formed the “Parkinson’s Prevalence Project” in 2014 to determine an updated estimate of the prevalence of Parkinson’s throughout North America. Prior estimates were deemed outdated and based on a small number of cases from small regional subpopulations – such as a study performed in a rural Mississippi county finding 26 cases was long used as the benchmark estimate for Parkinson’s prevalence in the US. The Parkinson’s Prevalence Project revised estimate draws from larger and more diverse populations and is almost double the previous estimate:

  • The research combined data from a multi-study sampling strategy in diverse geographic regions including California, Minnesota, Hawaii, and Ontario, Canada and compared those results to U.S. Medicare data.
  • The estimated overall prevalence of Parkinson’s among those 45 years old or older is 572 per 100,000, which translates into 680,000 individuals in the U.S. who are at least 45 years old with Parkinson’s in 2010, the date of the last official U.S. census.
  • The prevalence of Parkinson’s will rise to approximately 930,000 in 2020 and 1,238,000 in 2030 based on the U.S. Census Bureau population projections.

Connie Marras, MD, PhD, lead author on the study and movement disorder neurologist at the Movement Disorders Centre at Toronto Western Hospital, a Parkinson’s Foundation Center of Excellence and the Edmond J. Safra Program in Parkinson’s research said, “Like Alzheimer’s disease, Parkinson’s affects primarily older individuals and poses a significant health care burden, as well as a real challenge on how to care for the aging population over the coming decades.”

Added John L. Lehr, CEO of the Parkinson’s Foundation: “One million Americans living with Parkinson’s by 2020 highlights the growing importance of optimizing care and treatment for people with the disease today. We continue to support scientific research, including through our ‘Parkinson’s Outcomes Project,’ the largest clinical study of Parkinson’s in the world, to help better understand what causes the disease, how to treat it and potentially stop progression and improve the lives of everyone living with the disease.”

Later this year, the Parkinson’s Foundation will be leading phase two of the prevalence study to better understand, on a national scale, how many people are diagnosed each year with Parkinson’s as well as the rate of mortality of people with the disease.

For more information about Parkinson’s statistics, visit Parkinson.org/Statistics.

###

About the Parkinson’s Foundation 
The Parkinson’s Foundation makes life better for people with Parkinson’s disease by improving care and advancing research toward a cure. In everything we do, we build on the energy, experience and passion of our global Parkinson’s community. For more information, visit www.parkinson.org or call (800) 4PD-INFO (473-4636).

About Parkinson’s Disease 
Affecting nearly one million Americans and 10 million worldwide, Parkinson’s disease is the second-most common neurodegenerative disease after Alzheimer’s and is the 14th-leading cause of death in the United States. It is associated with a progressive loss of motor control (e.g., shaking or tremor at rest and lack of facial expression), as well as non-motor symptoms (e.g., depression and anxiety). There is no cure for Parkinson’s and 60,000 new cases are diagnosed each year in the United States alone.

 

Tuesday, July 10, 2018
Parkinson’s Foundation to Host “World Without Parkinson’s” Symposium on Thursday, June 1 to Mark 60th Anniversary
Wednesday, May 31, 2017

Scientific Progress in Next 20 Years Due to Outpace the Last 200

Parkinson’s Foundation Welcomes New Patient Advisors
Wednesday, May 24, 2017

Five New Members Added to Advisory Council to Improve Lives of People Living With Parkinson’s

New York, NY, and Miami, FL — The Parkinson’s Foundation is pleased to welcome five new members to its People with Parkinson’s Advisory Council.  The appointments reflect the foundation’s ongoing commitment to engage with the community in its work to create a world without Parkinson’s disease.

Fifth Annual Celebrate Spring Boston Raises More Than $30,000 for Parkinson’s Foundation
Thursday, May 11, 2017

Boston Area Residents Inspire Fellow Young Professionals to End Parkinson’s

Parkinson’s Foundation Welcomes Paul H. Nathan to Board of Directors
Wednesday, May 3, 2017

New York, NY and Miami, FL — The Parkinson’s Foundation is pleased to announce the election of financial services executive Paul H. Nathan of San Francisco, CA, to its Board of Directors. The appointment was announced following a meeting of the board on April 27.

Parkinson’s Foundation to Host “World Without Parkinson’s” Scientific Symposium on June 1 in NYC
Friday, April 21, 2017

The Parkinson’s Foundation invites health innovators to join World Without Parkinson’s on Thursday, June 1 in New York, NY. The cutting-edge scientific event marks the 200th anniversary of James Parkinson’s, “An Essay on the Shaking Palsy.”

FDA Allows Marketing of a Genetic Test for Medical Conditions Including Parkinson’s
Thursday, April 6, 2017

Earlier today, the US Food and Drug Administration (FDA) announced that it will allow direct marketing to consumers of a genetic test that identifies predispositions for 10 medical conditions, including Parkinson’s. Such tests are referred to as direct-to-consumer or DTC.

Parkinson’s Foundation to Host 60th Anniversary Gala on Wednesday, May 31
Monday, March 20, 2017

The 60th Anniversary Gala to benefit Parkinson’s Foundation will take place Wednesday, May 31, 2017 in the Garden Terrace Room at the New York Botanical Garden in the Bronx, NY.  The Gala marks the 60th Anniversary of both the Parkinson ’s Disease Foundation (PDF) and the National Parkinson Foundation (NPF), the legacy organizations of the Parkinson’s Foundation and recognizes their

Parkinson’s Foundation Mourns the Passing of Lewis P. Rowland, M.D.
Friday, March 17, 2017

The Parkinson’s Foundation mourns the loss of Lewis P. “Bud” Rowland, M.D., Emeritus member of its Board of Directors and longtime champion of its work to end Parkinson’s. Dr. Rowland, who also served as President of the Parkinson’s Disease Foundation (PDF) division of the Parkinson’s Foundation for many years, passed away on March 16.

Local Residents Raise Nearly $40,000 for Parkinson’s Research at Scotch & Sangria Event in Closter, NJ
Thursday, March 9, 2017

Proceeds From Fourth Annual Helping Hours Event Benefit Parkinson’s Foundation

Advocates Guide $16 Million in US Department of Defense Parkinson’s Research Funding for Second Straight Year
Tuesday, March 7, 2017

Recently, four Parkinson’s Foundation Research Advocates helped guide $16 million in government funding for Parkinson’s disease (PD) research. This is the second straight year in which our Research Advocates have served as consumer reviewers for research funded by the US Department of Defense (DoD). The group included:

Pages

mail icon

Subscribe to get the latest news on treatments, research and other updates.